ARTs safe without program lab tests.

Related StoriesNew pc model predicts levels of HIV care engagementStudy evaluates performance of antiretroviral treatment in HIV-infected childrenResearch provides leads for new strategies to develop HIV vaccineHealth-e also examines the outcomes of the DART trial and features responses by Francois Venter, president of the Southern Africa HIV Clinicians Society, and HIV/Helps advocate Gregg Gonsalves . DART outcomes have main implications for ART programmes in Africa at a time when there can be uncertainty about long-term funding and sustainability so when most people still cannot access treatment, the analysis authors conclude. With less have to provide routine monitoring, particularly for toxicity, funding can be centered on medication procurement, strengthening of diagnostic laboratory solutions, and training and guidance for health-care employees to foster quality scientific monitoring, to support scale-up of ART rollout to rural Africa where 60 percent of the HIV-infected population live .Experts used the BMI measures to model their projected development over time. They found that children with an ADHD diagnosis who had not taken any medication to treat their symptoms started growing bigger than their peers without the disorder as soon as age 10. Adding a stimulant medication changed that picture, however. Kids who had taken stimulants such as Ritalin and Concerta primarily lagged behind their unmedicated peers on the growth charts. Children who had been medicated the longest were about one to two BMI points smaller than their peers at age group 10, Schwartz said.